In this podcast, Dr. Sumanta Pal gives an overview of research that will be shared at the 2017 Genitourinary Cancers Symposium.

The 2017 Clinical Cancer Advances report of the American Society of Clinical Oncology has announced that the Advance of the Year is Immunotherapy 2.0. Why 2.0? Because the role of immunotherapy in cancer care is expanding, and oncologists are learning how to use it more effectively.

Recent FDA approvals for immunotherapy drugs for treating lung cancer are exciting, but there still are many things we need to learn about this new field of cancer treatment. Cancer.Net Associate Editor Jyoti Patel, MD, answers some of the questions that surround lung cancer and immunotherapy, during Lung Cancer Awareness Month.

These studies from the ASCO Annual Meeting show some of the newest thoughts and latest advances in using immunotherapy and targeted therapy to treat bladder, stomach, and lung cancers.

From June 3 to June 7, oncology professionals from around the world will meet to discuss the latest in cancer research. If you can’t wait to learn about the latest research, check here for early highlights released in advance of the 2016 ASCO Annual Meeting.

Immunotherapy made exciting strides in 2015. Because of its potential, ASCO named it the 2016 Clinical Cancer Advance of the Year.

Immunotherapy is one of the hottest topics in cancer research. This year, focus at the ASCO Annual Meeting has been on a type of immunotherapy called PD-1 inhibitors. Learn how these drugs may help improve the treatment of head and neck, liver, and lung cancers.